Theralase Technologies Inc
XTSX:TLT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (50), the stock would be worth CA$0.19 (50% downside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 100.3 | CA$0.39 |
0%
|
| 3-Year Average | 50 | CA$0.19 |
-50%
|
| 5-Year Average | 51.4 | CA$0.2 |
-49%
|
| Industry Average | 2.7 | CA$0.01 |
-97%
|
| Country Average | 2.9 | CA$0.01 |
-97%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
CA$70.8m
|
/ |
Oct 2025
CA$1m
|
= |
|
|
CA$70.8m
|
/ |
Dec 2025
CA$906.4k
|
= |
|
|
CA$70.8m
|
/ |
Dec 2026
CA$1.3m
|
= |
|
|
CA$70.8m
|
/ |
Dec 2027
CA$34.9m
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
|
Theralase Technologies Inc
XTSX:TLT
|
100.3m CAD | 100.3 | -23 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 16.4 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 3.5 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 5.4 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 3.6 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 4.9 | 25.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 2 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 7.2 | 44.6 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 10.6 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 2.7 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 5.7 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 2.9 |
| 70th Percentile | 5.7 |
| Max | 15 639 353.3 |
Other Multiples
Theralase Technologies Inc
Glance View
Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in East York, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light activated compounds and their associated drug formulations with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses. The firm operates through two divisions, The Anti-Cancer Therapy (ACT) and The Cool Laser Therapy (CLT). ACT division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. CLT division designs, develops, manufactures and markets patented, and its laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerves, muscle and joint conditions. The firm develops products both internally and using the assistance of external resources.
